Completed PHASE2 INTERVENTIONAL 2-arm NCT00665041

Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome

A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome

Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA

Conditions Ovarian Hyperstimulation Syndrome

Interventions Quinagolide

Updated 5 times since 2017 Last updated: Sep 16, 2009 Started: May 31, 2008 Primary completion: Aug 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovarian Hyperstimulation Syndrome, this trial is completed. The trial is conducted by Instituto Valenciano de Infertilidad, IVI VALENCIA and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto Valenciano de Infertilidad, IVI VALENCIA

Data source: Instituto Valenciano de Infertilidad, IVI VALENCIA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valencia, Spain